Yu Ruirui, Wang Zhoutian, Ma Miaomiao, Xu Ping, Liu Longjian, Tinkov Alexey A, Lei Xin Gen, Zhou Ji-Chang
School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China.
Shenzhen Health Development Research and Data Management Center, Shenzhen 518028, China.
Antioxidants (Basel). 2022 Jun 27;11(7):1263. doi: 10.3390/antiox11071263.
Selenoprotein P (SELENOP) is an extracellular antioxidant, selenium transporter, and hepatokine interfering with glucose and lipid metabolism. To study the association between the circulating SELENOP concentration and glucose and lipid metabolic diseases (GLMDs), including gestational diabetes (GD), metabolic syndrome (MetS), non-alcoholic fatty liver disease, obesity, and type 2 diabetes, as well as the individual markers, a meta-analysis was conducted by searching multiple databases from their establishment through March 2022 and including 27 articles published between October 2010 and May 2021, involving 4033 participants. Participants with GLMDs had higher levels of SELENOP than those without GLMDs (standardized mean difference = 0.84, 95% CI: 0.16 to 1.51), and the SELENOP levels were positively correlated with the markers of GLMDs (pooled effect size = 0.09, 95% CI: 0.02 to 0.15). Subgroup analyses showed that the SELENOP concentrations were higher in women with GD and lower in individuals with MetS than their counterparts, respectively. Moreover, SELENOP was positively correlated with low-density lipoprotein cholesterol, but not with the other markers of GLMDs. Thus, the heterogenicity derived from diseases or disease markers should be carefully considered while interpreting the overall positive association between SELENOP and GLMDs. Studies with a larger sample size and advanced design are warranted to confirm these findings.
硒蛋白P（SELENOP）是一种细胞外抗氧化剂、硒转运蛋白和干扰葡萄糖与脂质代谢的肝因子。为了研究循环SELENOP浓度与葡萄糖和脂质代谢疾病（GLMDs）之间的关联，包括妊娠期糖尿病（GD）、代谢综合征（MetS）、非酒精性脂肪性肝病、肥胖症和2型糖尿病，以及个体标志物，我们通过检索多个数据库（从其建立到2022年3月）并纳入2010年10月至2021年5月发表的27篇文章进行了一项荟萃分析，涉及4033名参与者。患有GLMDs的参与者的SELENOP水平高于未患GLMDs的参与者（标准化平均差 = 0.84，95%置信区间：0.16至1.51），并且SELENOP水平与GLMDs的标志物呈正相关（合并效应量 = 0.09，95%置信区间：0.02至0.15）。亚组分析表明，患有GD的女性的SELENOP浓度较高，而患有MetS的个体的SELENOP浓度分别低于其对应人群。此外，SELENOP与低密度脂蛋白胆固醇呈正相关，但与GLMDs的其他标志物无关。因此，在解释SELENOP与GLMDs之间的总体正相关关系时，应仔细考虑疾病或疾病标志物产生的异质性。需要进行更大样本量和更先进设计的研究来证实这些发现。
